Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib vs oral etoposide in recurrent or refractory pediatric ependymoma
2009-016836-11Phase 2Completed
- Sponsor
- OSI Pharmaceuticals
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in ependymoma comparing Erlotinib monotherapy with Oral etoposide monotherapy (2 arms). Primary endpoint: Objective response rate (CNS-specific criteria). Started Jan 2011; status: completed.
02
Drugs
erlotinibetoposide
03
Conditions
ependymoma
Beyond the preview
Go deeper on 2009-016836-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016836-11.